Carpal Tunnel Syndrome denials in California external review
In the California DMHC record, independent physician reviewers decided 36 published external-review cases involving carpal tunnel syndromeand overturned the plan’s denial in 47.2%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for carpal tunnel syndrome
| Category | Decisions | Overturned |
|---|---|---|
| Physical Therapy | 6 | 50% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 27 | 55.6% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 14.3% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for urgent medical services. One study notes that, “Distal radius fractures… are commonly the result of a fall on outstretched hands or high-energy trauma. On assessment, clinicians should determine the mechanism of injury, associated bony or soft tissue injuries, and neurovascular symptoms. Investigations should always include radiographs to evaluate for intra-articular involvement and fracture displacement. The preferred management should consider the severity of the fracture, desired functional outcome and patient comorbidities. Non-operative management in select patients can give good results. Immobilization with or without reduction forms the mainstay of non-operative treatment.
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for tramadol HCL. According to research, the use of a weak opioid in combination with an NSAID for pain control is indicated for mild to moderate pain and represents only the second step in the four-step ladder. Researchers have stated that medical necessity for chronic opioid therapy may be established on average moderate to severe pain (equal to 4, on a scale of 0 to 10) and/or disability. With regard to determining opioid dosage, researchers consider up to 40 morphine milligram equivalent (MME) as a low dose, from 41 to 90 MME as a moderate dose, and greater than 91 MME as a high dose. Medical literature states that clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has been diagnosed with right carpal tunnel syndrome and complex regional pain syndrome (CRPS). The provider noted that the patient underwent a right carpal tunnel release that was complicated by a postoperative infection requiring an incision and drainage procedure. The provider noted the patient had findings consistent with CRPS, including hyperhidrosis of the right-hand fingers, shiny skin, and nerve pain with proximal radiation. The patient was previously treated with a stellate ganglion block, which reportedly was not beneficial. The patient has also been treated with Lyrica and Valium. The patient was noted to be allergic to Pamelor, and she did not want to try another nerve pain medication. The provider noted a second surgery to release scar tissue could be beneficial.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for platelet-rich plasma injection to the right elbow. Platelet-rich plasma injection therapy is a technique using a concentrated portion of autologous blood in an attempt to augment and accelerate healing of various tissues. Review studies and national guidelines have not reported substantial improvement in patient health outcomes with use of platelet-rich plasma for the treatment of musculoskeletal disorders. Currently, data suggest that the use of platelet-rich plasma for most musculoskeletal soft tissue injuries should occur within the context of a well-designed clinical trial. There is a paucity of studies demonstrating the safety and efficacy of platelet-rich plasma for the treatment of chronic pain.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving carpal tunnel syndrome, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY